Keith Gottesdiener, Prime Medicine CEO
Prime Medicine whittles down pipeline, signs gene editing deal with Bristol Myers
Prime Medicine announced Monday morning that it is cutting its pipeline, and it signed a T cell therapy partnership with Bristol Myers Squibb for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
